文献速递其他结缔组织病

抗CCL24单抗CM-101改善实验性皮肤与肺纤维化

Blockade of CCL24 with a monoclonal antibody ameliorates experimental dermal and pulmonary fibrosis.
PubMed 文献 · Ann Rheum Dis · 2019-05-25

该研究检测了系统性硬化症(SSc)患者血清CCL24水平及皮损CCL24/CCR3表达,并在体外及博来霉素诱导动物模型中评估抗CCL24单抗CM-101的作用。结果显示SSc患者CCL24升高、皮损CCL24/CCR3表达增强,CM-101可抑制成纤维细胞活化及皮肤肺纤维化与炎症。

要点

  • SSc患者循环CCL24水平显著升高,皮损CCL24/CCR3表达明显增强
  • CM-101可抑制SSc血清诱导的成纤维细胞活化与肌成纤维细胞转化
  • 博来霉素模型中CM-101显著抑制皮肤和肺纤维化及炎症

核心结论

  • CCL24参与皮肤与肺炎症和纤维化病理过程,CM-101阻断CCL24可能对SSc患者有治疗获益。

研究设计与样本

  • 采用ELISA与荧光免疫组化检测SSc患者血清CCL24水平及皮肤活检CCL24/CCR3表达。
  • 体外以CCL24或SSc血清处理皮肤成纤维细胞与内皮细胞,加或不加CM-101观察活化与分化。
  • 体内采用博来霉素诱导模型的预防与治疗两种方案,评估CM-101对皮肤和肺纤维化进展的作用。

主要发现

  • SSc患者循环CCL24水平显著升高,SSc皮肤中CCL24/CCR3表达强烈增加。
  • CM-101阻断CCL24显著减少SSc血清诱导的皮肤成纤维细胞活化及其向肌成纤维细胞转化。
  • CM-101还能显著抑制CCL24诱导的内皮细胞活化。
  • 在博来霉素诱导动物模型中,CM-101深度抑制皮肤与肺纤维化及炎症。

临床怎么用

  • 结果支持在SSc中进一步开展靶向CCL24的临床转化研究,尚不能直接指导临床用药。

局限性

  • 证据主要来自体外实验与博来霉素诱导动物模型,尚需人体研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: We aimed to assess the expression of the CCL24 chemokine in systemic sclerosis (SSc) and to evaluate the possible pathogenic implications of the CCL24/CCR3 axis using both in vitro and in vivo models. We further investigated the efficacy of an anti-CCL24 monoclonal antibody (mAb), CM-101, in inhibiting cell activation as well as dermal and pulmonary inflammation and fibrosis in experimental animal models. METHODS: We used ELISA and fluorescence immunohistochemistry to determine CCL24 levels in serum and CCL24/CCR3 expression in skin biopsies of SSc patients. Skin fibroblasts and endothelial cells treated with CCL24 or SSc serum with or without CM-101 were used to follow cell activation and differentiation. Prevention and treatment in vivo bleomycin (BLM)-induced models were used to evaluate experimental dermal and pulmonary fibrosis progression following treatment with the CM-101 mAb. RESULTS: CCL24 circulating levels were significantly elevated in SSc patients. CCL24/CCR3 expression was strongly increased in SSc skin. Blockade of CCL24 with CM-101 significantly reduced the activation of dermal fibroblasts and their transition to myofibroblasts induced by SSc serum. CM-101 was also able to significantly inhibit endothelial cell activation induced by CCL24. In BLM-induced experimental animal models, CM-101 profoundly inhibited both dermal and pulmonary fibrosis and inflammation. CONCLUSIONS: CCL24 plays an important role in pathological processes of skin and lung inflammation and fibrosis. Inhibition of CCL24 by CM-101 mAb can be potentially beneficial for therapeutic use in SSc patients.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Mor A, Segal Salto M, Katav A, et al. Blockade of CCL24 with a monoclonal antibody ameliorates experimental dermal and pulmonary fibrosis. Ann Rheum Dis. 2019. PMID: 31129606. doi:10.1136/annrheumdis-2019-215119

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。